Skip to main navigation
Skip to main content
Skip to page footer
Back
Epsilico
Epsilico develops therapeutic proteins against hard-to-drug targets such as GPCRs, ion channels, and transporter proteins using generative AI and geometric deep learning models. The platform enables biophysical characterization of drug candidates within weeks, preparing them for pre-clinical testing. Target customers are pharmaceutical and biopharmaceutical companies focusing on diseases with unmet medical need.
